Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.

Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy

Fang, Yingxu, Wang, Jiaxing, Zhao, Min, Zheng, Qinwen, Ren, Changyu, Wang, Yuxi, Zhang, Jifa · 2022 · Journal of Medicinal Chemistry

Abstract

Neurodegenerative diseases (NDs) are currently incurable diseases that cause progressive degeneration of nerve cells. Many of the disease-causing proteins of NDs are “undruggable” for traditional small-molecule inhibitors (SMIs). None of the compounds that attenuated the amyloid-β (Aβ) accumulation process have entered clinical practice, and many phase III clinical trials of SMIs for Alzheimer’s disease (AD) have failed. In recent years, emerging targeted protein degradation (TPD) technologies such as proteolysis-targeting chimeras (PROTACs), lysosome-targeting chimaeras (LYTACs), and autophagy-targeting chimeras (AUTACs) with TPD-assistive technologies such as click-formed proteolysis-targeting chimeras (CLIPTACs) and deubiquitinase-targeting chimera (DUBTAC) have developed rapidly. In vitro and in vivo experiments have also confirmed that TPD technology can target the degradation of ND pathogenic proteins, bringing hope for the treatment of NDs. Herein, we review the latest TPD technologies, introduce their targets and technical characteristics, and discuss the emerging TPD technologies with potential in ND research, with the hope of providing a new perspective for the development of TPD technology in the NDs field.

Overview

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.2c00844

Cites

164 of 164 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 163 references

Research works printed but not linked: 2

  1. Citron B. A., 2015, Am. J. Neurodegener. Dis., 4, 40
  2. Bachstetter A. D., 2010, Aging Dis., 1, 199

Cited by

See all 111

Metadata

Authors
Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J.
Affiliations
  • Sichuan University (CN)
  • University of Tennessee Health Science Center (US)
  • Chengdu Fifth People's Hospital (CN)
Corresponding author
  • Wang, Yuxi
  • Zhang, Jifa
Venue
Journal of Medicinal Chemistry
Published
2022-08-25
Volume
65
Issue
17
Pages
11454-11477
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W4293102944
Cited by
100
References
163
Citations by year
2026: 16 · 2025: 34 · 2024: 28 · 2023: 20 · 2022: 2
FWCI
2.24
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Ministry of Science and Technology of the People's Republic of China (2018ZX09201018-021)
  • Health Commission of Sichuan Province (21PJ149)
  • Chinese Academy of Medical Sciences (2020-JKCS-014)
  • Natural Science Foundation of Sichuan Province (2022NSFSC1365)
  • Department of Science and Technology of Sichuan Province (2019YFS0003)
  • National Natural Science Foundation of China (81903502, 82073318)
  • Xinglin Foundation of Chengdu University (YYZX2021043)
  • West China Hospital, Sichuan University (ZYGD20001)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords
targeted protein degradation, neurodegenerative diseases, Alzheimer's disease, PROTACs, lysosome-targeting chimeras, undruggable proteins, amyloid-beta, protein degradation
MeSH terms
Chimera, Humans, Lysosomes, Proteins, Neurodegenerative Diseases, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy. https://app.cochat.ai/papers/10.1021/acs.jmedchem.2c00844
The paper
Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022). Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c00844

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.